Anebulo Pharmaceuticals Stock Alpha and Beta Analysis
| ANEB Stock | USD 1.16 0.03 2.65% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Anebulo Pharmaceuticals. It also helps investors analyze the systematic and unsystematic risks associated with investing in Anebulo Pharmaceuticals over a specified time horizon. Remember, high Anebulo Pharmaceuticals' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Anebulo Pharmaceuticals' market risk premium analysis include:
Beta (0.37) | Alpha (0.89) | Risk 6.09 | Sharpe Ratio (0.15) | Expected Return (0.92) |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Check out Anebulo Pharmaceuticals Backtesting, Anebulo Pharmaceuticals Valuation, Anebulo Pharmaceuticals Correlation, Anebulo Pharmaceuticals Hype Analysis, Anebulo Pharmaceuticals Volatility, Anebulo Pharmaceuticals History and analyze Anebulo Pharmaceuticals Performance. Anebulo Pharmaceuticals Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Anebulo Pharmaceuticals market risk premium is the additional return an investor will receive from holding Anebulo Pharmaceuticals long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Anebulo Pharmaceuticals. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Anebulo Pharmaceuticals' performance over market.| α | -0.89 | β | -0.37 |
Anebulo Pharmaceuticals expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Anebulo Pharmaceuticals' Buy-and-hold return. Our buy-and-hold chart shows how Anebulo Pharmaceuticals performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Anebulo Pharmaceuticals Market Price Analysis
Market price analysis indicators help investors to evaluate how Anebulo Pharmaceuticals stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Anebulo Pharmaceuticals shares will generate the highest return on investment. By understating and applying Anebulo Pharmaceuticals stock market price indicators, traders can identify Anebulo Pharmaceuticals position entry and exit signals to maximize returns.
| Price Series Summation | ||
| Price Series Division | ||
| Inverse Tangent Over Price Movement | ||
| Price Ceiling Movement | ||
| Aroon Oscillator | ||
| Balance Of Power | ||
| Parabolic SAR | ||
| MidPoint over period | ||
| Hanging Man | ||
| Long Line Candle |
Anebulo Pharmaceuticals Return and Market Media
The median price of Anebulo Pharmaceuticals for the period between Fri, Oct 10, 2025 and Thu, Jan 8, 2026 is 2.34 with a coefficient of variation of 21.87. The daily time series for the period is distributed with a sample standard deviation of 0.49, arithmetic mean of 2.23, and mean deviation of 0.33. The Stock received substential amount of media coverage during this period. Price Growth (%) |
| Timeline |
1 | Acquisition by Lawler Joseph F. of 6618 shares of Anebulo Pharmaceuticals at 2.1 subject to Rule 16b-3 | 10/17/2025 |
2 | Will Anebulo Pharmaceuticals Inc. stock attract ESG investors - July 2025 Fed Impact Weekly High Return Opportunities - newser.com | 10/31/2025 |
3 | Is Anebulo Pharmaceuticals Inc. stock resilient to inflation - Rate Cut Real-Time Volume Analysis Alerts - newser.com | 11/03/2025 |
4 | Risk Report Can Anebulo Pharmaceuticals Inc. stock rebound after recent weakness - Market Growth Report Consistent Income Trade Ideas - fcp.pa.gov.br | 11/06/2025 |
5 | Risk vs reward if holding onto Anebulo Pharmaceuticals Inc. - Global Markets High Conviction Trade Alerts - newser.com | 11/12/2025 |
6 | Will Anebulo Pharmaceuticals Inc. stock outperform value stocks - July 2025 Fed Impact Real-Time Market Trend Scan - newser.com | 11/21/2025 |
7 | Can Anebulo Pharmaceuticals Inc. stock deliver strong Q4 earnings - Market Volume Summary Safe Capital Growth Tips - Newser | 12/04/2025 |
8 | US Stocks Higher Nasdaq Surges Over 100 Points | 12/22/2025 |
9 | How Is The Market Feeling About Anebulo Pharmaceuticals Inc | 12/26/2025 |
About Anebulo Pharmaceuticals Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Anebulo or other stocks. Alpha measures the amount that position in Anebulo Pharmaceuticals has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2025 | 2026 (projected) | PB Ratio | 4.8 | 4.56 | Capex To Depreciation | 7.0E-6 | 6.0E-6 |
Anebulo Pharmaceuticals Upcoming Company Events
As portrayed in its financial statements, the presentation of Anebulo Pharmaceuticals' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Anebulo Pharmaceuticals' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Anebulo Pharmaceuticals' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Anebulo Pharmaceuticals. Please utilize our Beneish M Score to check the likelihood of Anebulo Pharmaceuticals' management manipulating its earnings.
| 9th of February 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 18th of September 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 30th of June 2023 Last Financial Announcement | View |
Build Portfolio with Anebulo Pharmaceuticals
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out Anebulo Pharmaceuticals Backtesting, Anebulo Pharmaceuticals Valuation, Anebulo Pharmaceuticals Correlation, Anebulo Pharmaceuticals Hype Analysis, Anebulo Pharmaceuticals Volatility, Anebulo Pharmaceuticals History and analyze Anebulo Pharmaceuticals Performance. For information on how to trade Anebulo Stock refer to our How to Trade Anebulo Stock guide.You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.
Anebulo Pharmaceuticals technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.